COMPANY

AN2 Therapeutics

HQ: Menlo Park, CA source · an2therapeutics.com ↗ · West Coast

Keywords: oncology infectious disease disease by infectious agent small molecule infectious diseases Melioidosis MAC Lung Disease Treatment Refractory MAC Lung Disease Renal Insufficiency Epetraborole AN2-502998

Location: Menlo Park, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

$40.0MRaised (2 yrs)6Trials (company is sponsor)4NIH grants

Timeline

Sep 28, 2026 Partnership Partnership / licensing announced Sep 28, 2026. Source: company's own press page. source ↗
Mar 10, 2026 Raise Private placement: $40M (total, as published), announced Mar 10, 2026. Source: SEC filing. source ↗ · Form D filed Mar 25, 2026 SEC Form D ↗
Aug 4, 2025 Trial start Phase 1: First-in-Human Trial of Oral AN2-502998 source ↗
Nov 1, 2023 Trial start —: An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis source ↗
Jun 5, 2023 Trial start Phase 1: A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects source ↗
May 20, 2022 Trial start Phase 2/Phase 3: Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease source ↗
Feb 21, 2022 Trial start Phase 1: A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function source ↗
Jun 10, 2021 Trial start 1: Phase 1 Study of Epetraborole Tablets source ↗

Funding

Raised: $40.0M. Last 2 years.

Mar 10, 2026 Private placement: $40M (total, as published), announced Mar 10, 2026. Source: SEC filing. source ↗ · Form D filed Mar 25, 2026 SEC Form D ↗
Sep 28, 2026 Partnership / licensing announced Sep 28, 2026. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT05327803	Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease	Phase 2/Phase 3	Terminated	May 20, 2022	Dec 18, 2024 (actual)
NCT07024589	First-in-Human Trial of Oral AN2-502998	Phase 1	Completed	Aug 4, 2025	Mar 14, 2026 (actual)
NCT06089668	An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis	Not listed	Completed	Nov 1, 2023	Oct 31, 2024 (actual)
NCT04892641	Phase 1 Study of Epetraborole Tablets	1	Completed	Jun 10, 2021	Feb 26, 2022 (actual)
NCT05995444	A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects	Phase 1	Completed	Jun 5, 2023	Jul 26, 2023 (actual)
NCT05283746	A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function	Phase 1	Completed	Feb 21, 2022	Jun 10, 2022 (actual)

NIH awards 4

Annual award amounts. Total $9.2M.

2025 NIH contract (government contract; not a grant and not an investment round) 75N93022C00059-P00008-9999-1 FY2025: $456,766 awarded for that fiscal year; activity N01 (OTHER_NIH); PI ALLEY, M.R.K. (DICKON); recipient as written: AN2 THERAPEUTICS, INC., MENLO PAR source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 75N93022C00059-P00004-9999-1 FY2024: $3,821,365 awarded for that fiscal year; activity N01 (OTHER_NIH); PI ALLEY, M.R.K. (DICKON); recipient as written: AN2 THERAPEUTICS, INC., MENLO P source ↗
2023 NIH contract (government contract; not a grant and not an investment round) 75N93022C00059-P00002-9999-1 FY2023: $651,041 awarded for that fiscal year; activity N01 (OTHER_NIH); PI ALLEY, M.R.K. (DICKON); recipient as written: AN2 THERAPEUTICS, INC., MENLO PAR source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 75N93022C00059-0-9999-1 FY2022: $4,306,405 awarded for that fiscal year; activity N01 (OTHER_NIH); PI ALLEY, M.R.K. (DICKON); recipient as written: AN2 THERAPEUTICS, INC., MENLO PARK, source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-03-25 Raise Private raise (SEC Form D): $40.0M sold; issuer “AN2 Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗